The “first treatable” form of CMT?

A teal double helix with evenly spaced rungs, one of which is violet and broken in the middle.

I wrote this brief article on the way the SORD gene works (or fails to work) for the Hereditary Neuropathy Foundation. SORD mutations cause “the most common autosomal recessive form of CMT2 (OMIM #618912), autosomal recessive intermediate CMT, and the overlapping category of distal hereditary motor neuropathy (dHMN).”

As I explain in the article, “CMT2 and dHMN are under-diagnosed rare disease categories, and up to nearly 10% of the [undiagnosed] cases that fall within them may be SORD-related.”

The way this type of CMT works — the way nerves are damaged in it — has to do with the body’s inability to produce sorbitol dehydrogenase (SDH), an enzyme the SORD gene encodes. Without SDH your body can’t convert sorbitol into fructose, which is a key part of what’s known as “the polyol pathway.” (This is how glucose is converted to sorbitol and then to fructose.) When sorbitol builds up too much in cells, they can be damaged and destroyed. This appears to happen to mitochondria in nerves, leading to the type of largely axonal damage that characterizes this type of CMT. (The exact mechanism of the damage is not known yet.) Reducing sorbitol levels in people with SORD Deficiency should be possible using existing drugs for diabetics — Applied Therapeutics is working on it.

Update, October 2026: Applied Therapeutics’ drug for SORD deficiency, govorestat (AT-007), missed the primary endpoint of its INSPIRE trial (a 10-metre walk-run test at 12 months) in May 2025, though the company pointed to a significant improvement on the CMT Health Index, a secondary measure (Fierce Biotech, May 2025). As of November 2025, the FDA had not accepted sorbitol levels as a surrogate endpoint, and the company had not settled on a path to a drug application (Fierce Biotech, November 2025). A planned confirmatory trial (NCT07191912) is listed as withdrawn (trial listing). I tell the rest of the story, including the end of every govorestat study in April 2026, in Three “Treatable CMT” Stories, and What the Market Taught Us.

Sorbitol dehydrogenase deficiency with peripheral neuropathy (SORDD) may end up with a treatment, but it may not be classified as CMT at that point.

Last updated:

Comments

One response to “The “first treatable” form of CMT?”

  1. […] and reclassification. That’s the effect it’s had on me since I first wrote about it here and for the Hereditary Neuropathy Foundation. (I was also tested for the SORD mutation since I have […]

Leave a Reply

Your email address will not be published. Required fields are marked *